000140821 001__ 140821
000140821 005__ 20240229105116.0
000140821 0247_ $$2doi$$a10.1016/j.molmet.2018.09.005
000140821 0247_ $$2pmid$$apmid:30287091
000140821 0247_ $$2altmetric$$aaltmetric:48819949
000140821 037__ $$aDKFZ-2018-01585
000140821 041__ $$aeng
000140821 082__ $$a610
000140821 1001_ $$aSchumacher, Dagmar$$b0
000140821 245__ $$aCompensatory mechanisms for methylglyoxal detoxification in experimental & clinical diabetes.
000140821 260__ $$aOxford [u.a.]$$bElsevier$$c2018
000140821 3367_ $$2DRIVER$$aarticle
000140821 3367_ $$2DataCite$$aOutput Types/Journal article
000140821 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1544432239_1367
000140821 3367_ $$2BibTeX$$aARTICLE
000140821 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000140821 3367_ $$00$$2EndNote$$aJournal Article
000140821 520__ $$aThe deficit of Glyoxalase I (Glo1) and the subsequent increase in methylglyoxal (MG) has been reported to be one the five mechanisms by which hyperglycemia causes diabetic late complications. Aldo-keto reductases (AKR) have been shown to metabolize MG; however, the relative contribution of this superfamily to the detoxification of MG in vivo, particularly within the diabetic state, remains unknown.CRISPR/Cas9-mediated genome editing was used to generate a Glo1 knock-out (Glo1-/-) mouse line. Streptozotocin was then applied to investigate metabolic changes under hyperglycemic conditions.Glo1-/- mice were viable and showed no elevated MG or MG-H1 levels under hyperglycemic conditions. It was subsequently found that the enzymatic efficiency of various oxidoreductases in the liver and kidney towards MG were increased in the Glo1-/- mice. The functional relevance of this was supported by the altered distribution of alternative detoxification products. Furthermore, it was shown that MG-dependent AKR activity is a potentially clinical relevant pathway in human patients suffering from diabetes.These data suggest that in the absence of GLO1, AKR can effectively compensate to prevent the accumulation of MG. The combination of metabolic, enzymatic, and genetic factors, therefore, may provide a better means of identifying patients who are at risk for the development of late complications caused by elevated levels of MG.
000140821 536__ $$0G:(DE-HGF)POF3-311$$a311 - Signalling pathways, cell and tumor biology (POF3-311)$$cPOF3-311$$fPOF III$$x0
000140821 588__ $$aDataset connected to CrossRef, PubMed,
000140821 7001_ $$aMorgenstern, Jakob$$b1
000140821 7001_ $$aOguchi, Yoko$$b2
000140821 7001_ $$aVolk, Nadine$$b3
000140821 7001_ $$aKopf, Stefan$$b4
000140821 7001_ $$aGroener, Jan Benedikt$$b5
000140821 7001_ $$0P:(DE-HGF)0$$aNawroth, Peter Paul$$b6
000140821 7001_ $$aFleming, Thomas$$b7
000140821 7001_ $$aFreichel, Marc$$b8
000140821 773__ $$0PERI:(DE-600)2708735-9$$a10.1016/j.molmet.2018.09.005$$gp. S2212877818302047$$p143-152$$tMolecular metabolism$$v18$$x2212-8778$$y2018
000140821 909CO $$ooai:inrepo02.dkfz.de:140821$$pVDB
000140821 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b6$$kDKFZ
000140821 9131_ $$0G:(DE-HGF)POF3-311$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vSignalling pathways, cell and tumor biology$$x0
000140821 9141_ $$y2018
000140821 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMOL METAB : 2017
000140821 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000140821 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000140821 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000140821 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central
000140821 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000140821 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000140821 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review
000140821 915__ $$0LIC:(DE-HGF)CCBYNCNDNV$$2V:(DE-HGF)$$aCreative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND (No Version)$$bDOAJ
000140821 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000140821 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000140821 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000140821 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000140821 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bMOL METAB : 2017
000140821 9201_ $$0I:(DE-He78)A170-20160331$$kA170$$lMolekulare Stoffwechselkontrolle$$x0
000140821 980__ $$ajournal
000140821 980__ $$aVDB
000140821 980__ $$aI:(DE-He78)A170-20160331
000140821 980__ $$aUNRESTRICTED